Boehringer's Survodutide Shows Breakthrough Results in Obesity Trials

Boehringer's Survodutide Shows Breakthrough Results in Obesity Trials

Boehringer Ingelheim's survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting improved metabolic health in people living with obesity

Boehringer's Survodutide Shows Breakthrough Results in Obesity Trials

Boehringer Ingelheim has revealed promising results from two major Phase III trials of its drug survodutide. The studies focused on weight loss in adults with obesity or overweight who do not have type 2 diabetes. Findings were shared at the American Diabetes Association’s 2026 Scientific Sessions.

The first trial, SYNCHRONIZE-1, examined survodutide’s effect on weight reduction. Its results were published in The New England Journal of Medicine. The drug showed clear potential to help participants lose weight effectively.

The second trial, SYNCHRONIZE-MASLD, looked at metabolic health improvements. It involved adults with overweight or obesity who also had metabolic dysfunction-associated steatotic liver disease (MASLD) with inflammation or fibrosis. These findings appeared in *Nature Medicine*. Both studies confirmed survodutide’s ability to address weight-related health issues. The data was presented in detail at the ADA’s annual conference, highlighting the drug’s broader benefits beyond simple weight loss.

The trial outcomes suggest survodutide could become a valuable treatment for obesity and related metabolic conditions. With results now published in leading medical journals, further review by health authorities is expected. The drug’s dual focus on weight reduction and liver health marks a significant step in metabolic disease research.

Neueste Nachrichten